[go: up one dir, main page]

WO2020179712A1 - Procédés de prédiction de la réponse tumorale à l'éribuline - Google Patents

Procédés de prédiction de la réponse tumorale à l'éribuline Download PDF

Info

Publication number
WO2020179712A1
WO2020179712A1 PCT/JP2020/008485 JP2020008485W WO2020179712A1 WO 2020179712 A1 WO2020179712 A1 WO 2020179712A1 JP 2020008485 W JP2020008485 W JP 2020008485W WO 2020179712 A1 WO2020179712 A1 WO 2020179712A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
eribulin
expression
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/008485
Other languages
English (en)
Inventor
Roma KAUL
Susan L. Mooberry
April L. RISINGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of WO2020179712A1 publication Critical patent/WO2020179712A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés, des compositions et des kits pour déterminer des approches pour le traitement du cancer, ainsi que des méthodes de traitement du cancer.
PCT/JP2020/008485 2019-03-01 2020-02-28 Procédés de prédiction de la réponse tumorale à l'éribuline Ceased WO2020179712A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962812836P 2019-03-01 2019-03-01
US62/812,836 2019-03-01

Publications (1)

Publication Number Publication Date
WO2020179712A1 true WO2020179712A1 (fr) 2020-09-10

Family

ID=72338722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/008485 Ceased WO2020179712A1 (fr) 2019-03-01 2020-02-28 Procédés de prédiction de la réponse tumorale à l'éribuline

Country Status (1)

Country Link
WO (1) WO2020179712A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113512733A (zh) * 2021-05-13 2021-10-19 浙江工业大学 一种电化学nhk反应合成艾日布林中间体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509515A (ja) * 2011-03-18 2014-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンに対する応答を予測するための方法及び組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509515A (ja) * 2011-03-18 2014-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンに対する応答を予測するための方法及び組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COOMBES R C; ARMSTRONG A; AHMED S; PAGE K; HASTINGS R K; SALARI R; SETHI H; BOYDELL A R; SHCHEGROVA S V; FERNANDEZ-GARCIA D; GLEAS: "Abstract P4-01-02: Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 79, no. 4, Supplement 1, Abstract P4-01-02, 1 February 2019 (2019-02-01), US, XP009514404, ISSN: 1538-7445, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/79/4_Supplement/P4-01-02> DOI: 10.1158/1538-7445.SABCS18-P4-01-02 *
KAUL ROMA; RISINGER APRIL L.; MOOBERRY SUSAN L.: "Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 121, no. 7, 4 September 2019 (2019-09-04), GB, pages 611 - 621, XP036895370, ISSN: 0007-0920, DOI: 10.1038/s41416-019-0556-9 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113512733A (zh) * 2021-05-13 2021-10-19 浙江工业大学 一种电化学nhk反应合成艾日布林中间体的方法

Similar Documents

Publication Publication Date Title
JP2019150027A5 (fr)
JP2014509515A5 (fr)
Wang et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer
US10345309B2 (en) Biomarkers for gastric cancer and uses thereof
Tang et al. High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma
JP2015517801A5 (fr)
Miyamoto et al. Significance of progesterone receptor-A and-B expressions in endometrial adenocarcinoma
US12366574B2 (en) Keratin 17 as a biomarker for bladder cancer
CN102625849B (zh) 侦测致死细胞的方法与材料及其应用
Lankiewicz et al. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment
RU2015118294A (ru) Синтетическая летальность и лечение рака
JP2015503922A (ja) 乳癌の予測および診断のためのバイオマーカー
KR20110065512A (ko) 암의 진단 방법 및 암 환자의 전반적 생존 및 무질병 생존의 측정 방법
Chen et al. GP73 is down-regulated in gastric cancer and associated with tumor differentiation
Zhao et al. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma
KR102000387B1 (ko) 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
CA3112792A1 (fr) Methode de selection pour le traitement d&#39;individus presentant un risque de cancer du sein invasif
WO2020179712A1 (fr) Procédés de prédiction de la réponse tumorale à l&#39;éribuline
WO2023234422A1 (fr) Procédé de test de tissu lymphoïde tertiaire, et kit de test de tissu lymphoïde tertiaire
EP3545108A1 (fr) Biomarqueurs destinés au prognostic et au diagnostic du cancer
Peng et al. Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
Niu et al. Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics
Phadke et al. A novel and accurate microfluidic assay of CD62L in bladder cancer serum samples
WO2019046807A1 (fr) Profilage phénotypique de cellules tumorales circulantes d&#39;un carcinome hépatocellulaire pour la sélection d&#39;un traitement
TW202317990A (zh) 用於預測乳癌預後情形的方法及套組

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20766622

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20766622

Country of ref document: EP

Kind code of ref document: A1